pyrazines has been researched along with minocycline in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chopp, M; Zhang, L; Zhang, ZG | 1 |
| Dougherty, PM; Robinson, CR; Zhang, H | 1 |
| Appolinario, CM; Jackson, AC | 1 |
| Hirota, T; Itoh, K; Iwasaki, H; Sakamaki, I | 1 |
2 review(s) available for pyrazines and minocycline
| Article | Year |
|---|---|
The neurovascular unit and combination treatment strategies for stroke.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebral Hemorrhage; Drug Therapy, Combination; Erythropoietin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Minocycline; Pyrazines; Stroke; Tissue Plasminogen Activator | 2012 |
Antiviral therapy for human rabies.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Central Nervous System; Combined Modality Therapy; Contraindications; Humans; Immunologic Factors; Minocycline; Molecular Targeted Therapy; Neuroprotective Agents; Pyrazines; Rabies; Rabies virus; RNA, Small Interfering; Virus Assembly; Virus Release | 2015 |
2 other study(ies) available for pyrazines and minocycline
| Article | Year |
|---|---|
Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat.
Topics: Animals; Antineoplastic Agents; Astrocytes; Boronic Acids; Bortezomib; Glial Fibrillary Acidic Protein; Hyperalgesia; Male; Microglia; Minocycline; Neuroprotective Agents; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Spinal Nerves | 2014 |
Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Minocycline; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2022 |